Polidocanol Sclerotherapy in Pyogenic Granulomas.
Adolescent
Adult
Child
Child, Preschool
Cost-Benefit Analysis
Drug Costs
Female
Granuloma, Pyogenic
/ economics
Humans
Injections, Intralesional
Male
Middle Aged
Polidocanol
/ administration & dosage
Recurrence
Sclerosing Solutions
/ administration & dosage
Sclerotherapy
/ adverse effects
Secondary Prevention
/ methods
Young Adult
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
25
11
2021
medline:
6
1
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
Polidocanol is a safe sclerosing agent with anesthetic properties and minimal skin toxicity. To evaluate the efficacy, safety, and recurrence rates with polidocanol sclerotherapy in the treatment of pyogenic granulomas (PGs). Thirty-nine patients with PG were injected with polidocanol 1% solution. Repeat injections were given weekly in case of incomplete clinical/dermoscopic resolution, until a maximum of 3 sittings. A higher strength (3%) was used for subsequent sessions in those with a minimal response to 1% solution. A final assessment for relapses was performed at 3, 6, and 12 months. All 39 patients achieved complete resolution (100% clearance rate), with most (n = 26) lesions resolving after the first sitting. Side effects noted were postprocedure pain (22), erythema (2), superficial ulceration (2), paresthesias (1), prominent edema (4), thrombophlebitis (1), cyanotic discoloration (1), purpuric staining around injection site (4), and mild local pruritus (1). The procedure was well tolerated across the age spectrum (4-63 years) included. We report polidocanol to be a highly effective, safe, and cost-effective sclerosant for treatment of PGs with no recurrences or need for special postprocedure care.
Sections du résumé
BACKGROUND
BACKGROUND
Polidocanol is a safe sclerosing agent with anesthetic properties and minimal skin toxicity.
OBJECTIVE
OBJECTIVE
To evaluate the efficacy, safety, and recurrence rates with polidocanol sclerotherapy in the treatment of pyogenic granulomas (PGs).
METHODS AND METHODS
METHODS
Thirty-nine patients with PG were injected with polidocanol 1% solution. Repeat injections were given weekly in case of incomplete clinical/dermoscopic resolution, until a maximum of 3 sittings. A higher strength (3%) was used for subsequent sessions in those with a minimal response to 1% solution. A final assessment for relapses was performed at 3, 6, and 12 months.
RESULTS
RESULTS
All 39 patients achieved complete resolution (100% clearance rate), with most (n = 26) lesions resolving after the first sitting. Side effects noted were postprocedure pain (22), erythema (2), superficial ulceration (2), paresthesias (1), prominent edema (4), thrombophlebitis (1), cyanotic discoloration (1), purpuric staining around injection site (4), and mild local pruritus (1). The procedure was well tolerated across the age spectrum (4-63 years) included.
CONCLUSION
CONCLUSIONS
We report polidocanol to be a highly effective, safe, and cost-effective sclerosant for treatment of PGs with no recurrences or need for special postprocedure care.
Identifiants
pubmed: 34816819
doi: 10.1097/DSS.0000000000003308
pii: 00042728-202201000-00017
doi:
Substances chimiques
Sclerosing Solutions
0
Polidocanol
0AWH8BFG9A
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-75Informations de copyright
Copyright © 2021 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Plachouri KM, Georgiou S. Therapeutic approaches to pyogenic granuloma: an updated review. Int J Dermatol 2019;58:642–8.
Matsumoto K, Nakanishi H, Seike T, Koizumi Y, et al. Treatment of pyogenic granuloma with a sclerosing agent. Dermatol Surg 2001;27:521–3.
Moon SE, Hwang EJ, Cho KH. Treatment of pyogenic granuloma by sodium tetradecyl sulfate sclerotherapy. Arch Dermatol 2005;141:644–6.
Carvalho RA, Neto V. Letter: polidocanol sclerotherapy for the treatment of pyogenic granuloma. Dermatol Surg 2010;36(Suppl 2):1068–70.
Daya M. Complete resolution of a recurrent giant pyogenic granuloma on the palm of the hand following single dose of intralesional bleomycin injection. J Plast Reconstr Aesthet Surg 2010;63:e331–3.
Kawanabe T, Wakita S, Harii K, Hayashi N, et al. Sclerotherapy of hemangiomas and vascular malformations in lips. J Jpn P R S 1996;16:852–62.
Ebrahimi SRS, Enamzadeh E, Babaei H. An evidence-based review of off-label uses of polidocanol. Curr Clin Pharmacol 2017;12:223–30.
Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: a review. J Plast Reconstr Aesthet Surg 2011;64:1216–20.
Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma - the quest for optimum treatment: audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg 2007;60:1030–5.
Koo MG, Lee SH, Han SE. Pyogenic granuloma: a retrospective analysis of cases treated over a 10-year. Arch Craniofac Surg 2017;18:16–20.
Patrice SJ, Wiss K, Mulliken JB. Pyogenic granuloma (lobular capillary hemangioma): a clinicopathological study of 178 cases. Pediatr Dermatol 1991;8:267–76.
Quitkin HM, Rosenwasser MP, Strauch RJ. The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am 2003;28:435–8.
Khurana A, Mathachan SR. Efficacy of bleomycin as a treatment modality in pyogenic granuloma: a case series. Dermatol Ther 2021;34:e15024.
Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, et al.; Guideline Group. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014;29:338–54.
Yamaki T, Sasaki Y, Hasegawa Y, Osada A, et al. Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations. J Vasc Surg Venous Lymphat Disord 2017;5:707–14.
Aoyama T, Fukumoto A, Shigita K, Asayama N, et al. Successful endoscopic sclerotherapy using polidocanol for small bowel hemangioma. Intern Med 2020;59:1727–30.
Liu JL, Zhang AQ, Jiang LC, Li KY, et al. The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland. J Oral Pathol Med 2018;47:895–9.
Duffy DM. Sclerosants: a comparative review. Dermatol Surg 2010;36(Suppl 2):1010–25.
Conrad P, Malouf GM, Stacey MC. The Australian polidocanol (aethoxysklerol) study. Dermatol Surg 1995;21:334–6.
Goldman MP. Treatment of varicose and telangiectatic leg veins: double blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatol Surg 2002;28:52.